Key Highlights
- Haemonetics shares are up 6.58% in pre-market trading to $96.21, extending a strong post-earnings run.
- The company's fiscal Q1 2027 report, released August 6, beat expectations with 5.6% Revenue growth to $339.4 million, and management raised full-year guidance to 5-8% reported growth.
- Bullish analyst commentary this week has highlighted the stock as significantly undervalued, with Fair Value estimates near $97 to $177 versus recent closes around $90.
- Continued buying interest is being fueled by strong quality metrics, including 27.5% EBIT growth, 24% ROIC, and 140% cash conversion, even as broader healthcare peers trade mixed amid macro headwinds from rising oil prices and bond yields.
What's Driving the Move
Haemonetics (NYSE:HAE) shares are surging in pre-market trading, extending a strong run that followed the company's most recent quarterly report. Haemonetics is a global medical technology company headquartered in Boston, Massachusetts, dedicated to improving the quality, effectiveness, and efficiency of healthcare through innovative medical products and solutions, operating across Plasma, Blood Center, and Hospital Business segments.
The rally traces back to the company's fiscal Q1 2027 report, released August 6, which beat expectations with 5.6% revenue growth to $339.4 million. Management also raised full-year guidance to a range of 5% to 8% reported growth, signaling confidence in the business's trajectory. The company's product portfolio spans automated plasma collection systems, donor management software, apheresis equipment, hemostasis analyzers, and autologous blood recovery systems, alongside advanced interventional technologies such as vascular closure devices.
Analysts Flag Undervaluation
Bullish analyst commentary this week has further fueled buying interest, with several analysts highlighting the stock as significantly undervalued relative to fair value estimates ranging from approximately $97 to $177, well above recent trading levels around $90. The bullish case is being reinforced by strong quality metrics, including 27.5% EBIT growth, 24% return on invested capital, and 140% cash conversion, even as broader healthcare peers trade mixed amid macro headwinds from rising oil prices and bond yields.
Conclusion
Haemonetics shares are sharply higher in pre-market trading as strong post-earnings fundamentals and fresh analyst commentary calling the stock undervalued combine to sustain the recent rally. With fair value estimates well above current trading levels and raised full-year guidance in place, the stock's next moves will likely hinge on continued execution across its plasma, blood center, and hospital segments.






Please wait processing your request...